Strand V, Kaeley GS, Bergman MJ, Gladman DD, Coates LC, Sherif B, Hur P, Parikh B, Gilloteau I, Mease PJ. The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomized phase 3 trial. Lancet Rheumatol. 2022 Mar 1;4(3):e208-19.
Ueda K, Takura T, Fujikoshi S, Meyers J, Nagar SP, Enomoto H. Longitudinal assessment of pain management among the employed Japanese population with knee osteoarthritis. Clin Interv Aging. 2020 Jun 26;2020(15):1003-12. doi: 10.2147/CIA.S242083
Pladevall M, Divine G, Wells KE, Resnicow K, Williams LK. A randomized controlled trial to provide adherence information and motivational interviewing to improve diabetes and lipid control. Diabetes Educ. 2015 Feb;41(1):136-46.
Davis KL, Wei W, Meyers JL, Kilpatrick BS, Pandya N. Use of basal insulin and the associated clinical outcomes among elderly nursing home residents with type 2 diabetes mellitus: a retrospective chart review study. Clin Interv Aging. 2014 Oct 23;2014(9):1815-22. doi: 10.2147/CIA.S65411
Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res. 2013 Oct;150(1):58-63.
Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsà F, López-Carrilero R, Carral V, Haro JM, Usall J. REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res. 2012 Dec;142(1-3):137-44. doi: 10.1016/j.schres.2012.08.035.
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.
Williams GC, Patrick H, Niemiec CP, Williams LK, Divine G, Lafata JE, Heisler M, Tunceli K, Pladevall-Vila M. Reducing the health risks of diabetes: how self-determination theory may help improve medication adherence and quality of life. Diabetes Educ. 2009 Mar 26;35(3):484-92.